Immune checkpoint inhibitors that target programmed cell death 1 (PD-1) or its ligand (PD-L1), either alone or in combination with anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), have demonstrated effectiveness in treating patients with metastatic NSCLC. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.